RICERCA ITALIANA     

Similar research programs:

• 1 - PURINOCEPTORS AND NEUROPROTECTION
• 2 - Glutamate-mediated neurotransmission: structural organization of the synapse, receptors and their role in pathophysiology
• 3 - PURINOCEPTORS AND NEUROPROTECTION
• 4 - Identification, functional expression and patho-physiological characterisation of novel purine receptors.
• 5 - Transcriptomic and proteomic studies in human heart failure for the identification of novel pathogenic mechanisms and biomarkers: focus on purinergic P2 receptors.
• 6 - G protein-coupled receptors: insights into mechanisms of signal transduction
• 7 - Metabotropic glutamate receptor subtypes as targets for neuroprotective agents
• 8 - CELL CYCLE CONTROL BY LIGANDS OF NUCLEAR RECEPTORS
• 9 - Neurotransmitter-mediated modulation of AMPA receptor function: implications in physiological transmission and pathology
• 10 - negative regulation of oncogenic receptor signalling: implications for cancer therapy

Scientific and education field classification

• Field: Scienze biologiche
  • FISIOLOGIA
  • FARMACOLOGIA
• Field: Scienze mediche

International Patent Classification

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF (biocides, pest repellants or attractants, or plant growth regulators, containing micro-organisms, viruses, microbial fungi, enzymes, fermentates or substances produced by or extracted from micro-organisms or animal material A01N63/00; food compositions A21, A23; medicinal preparations A61K; chemical aspects of, or use of materials for, bandages, dressings, absorbent pads or surgical articles A61L; fertilisers C05); PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS (preservation of living parts of humans or animals A01N1/02); MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (micro-biological testing media C12Q)
  • ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B3/00, C25B7/00)
    • PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Geographical classification

• Region: Lombardia

Bibliografia

1. Bouvier M 2001 Oligomerization of G protein-coupled transmitter receptors. Nat Neurosci 2:274

2. Agnati LF, Ferré S, Lluis C, Franco F, Fuxe K 2003 Molecular mechanisms and therapeutical implications of intramembrane receptor-receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol Rev 55:509

3. Fuxe K, Agnati LF 1985 Receptor/receptor interactions in the central nervous system. A new integrative mechanism in synapses. Med Res Rev 5:441

4. Agnati LF, Franzén O, Ferré S, Franco R, Fuxe K 2003 Possible role of intramembrane receptor/receptor interaction in memory and learning via formation of long-lived heteromeric complexes:focus on motor learning in basal ganglia. J Neural Trans 65:195

5. Angers S, Salahpour A, Bouvier M 2002 Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. Annu Rev Pharmacol Toxicol 42:409

6. Devi LA 2001 Heterodimerization of G-Pprotein-coupled receptors: pharmacology, signalling and trafficking. Trends Pharmacol Sci 22:532

7. Nicola SM, Surmeier DJ, Malenka RC 2000 Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu Rev Neurosci 23:185

8. Gerfen CR 1992 The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 15:133

9. Smith AD, Bolam JP 1990 The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurons. Trends Neurosci 13:259

10. Graybiel AM 1990 Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 13:133

11. Missale C, Nash R, Robinson SW, Jaber M, Caron MG 1998 Dopamine receptors: from structure to function. Physiol Rev 78:189

12. Surmeier DJ, Song WJ, Yan Z 1996 Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci 16:6579

13. Olanow CW, Obeso JA, Nutt JG 2000 Basal ganglia, Parkinson’s disease and levodopa therapy. Trends Neurosci suppl 23:1-126

14. Hollmann M, Heinemann S 1994 Cloned glutamate receptors. Ann Rev Neurosci 17:31

15. Landwehrmeyer GB, Standaert DG, Testa CM, Penney JB, Young AB 1995 NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J Neurosci 15:5297

16. Fiorentini C, Gardoni F, Spano PF, DiLuca M, Missale C 2003 Regulation of dopamine D1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-D-aspartate receptors. J Biol Chem 278:20196

17. Snyder SH 1985 Adenosine as a neuromodulator. Ann Rev Neurosci 8:103

18. Fredholm BB, Uzerman AP, Jacobson KA, Klotz KN, Linden J 2001 Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527

19. Schiffman SN, Jacobs O, Vanderhaeghen JJ 1991 Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not substance P neurons: an in situ hybridization histochemistry study. J Neurochem 57:1062

20. Fink JS, Weaver DR, Rivkees SA, peterfreund RA, Pollack A, Adler EM, Reppert SM 1992 Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Mol Brain Res 14:186

21. Ferré S, O’Connor WT, Svennungsson P, Bjorklund L, Lindberg J, Tinner B, Stromberg I, Goldstein M, Ogren SO, Ungerstedt U 1996 Dopamine D1 receptor-mediated facilitation of GABAergic neurotransmission in the rat striato-peduncular pathway and its modulation by adenosine A1-mediated mechanisms. Eur J Neurosci 8:1545 <br />
22. Canals M, Marcellino D, Fanelli F, Ciruela F, De Benedetti P, Goldberg SR, Fuxe K, Agnati L, Woods A, Lluis C, Bouvier M, Franco R 2003 Adenosine A2A-dopamine D2 receptor-receptor heteromerization. J Biol Chem 278:46741

23. Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, Hansson A, Watson S, Olah ME, Mallol J, Canela EI, Zoli M, Agnati LF et al. 2002 Coaggregation, cointernalization and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 277:18091

24. Ferré S, Karacz-Kubicha M, Hope BT, Popoli P, Burgueno J, Gutierrez MA, Casado V, Fuxe K et al.2002 Synergistic interaction between adenosine A2A and glutamate mGluR5 receptors: implication for striatal neuronal function. Proc Natl Acad Sci USA 99:11940

25. Ginés S, Hillion J, Torvinen M, LeCrom S, Casado V, Canela E, Rondin S, Lew J, Watson S, Zoli M, Agnati LF, et al. 2000 Dopamine D1 and adenosine A1 receptors assemble into functionally interacting heteromeric complexes. Proc Natl Acad Sci USA 97:8606

26. Lee FJ, Xue S, Pei L, Vukusic B, Chery N, Wang Y, Wang YT, Niznik HB, Yu XM, Liu F. 2002 Dual regulation of NMDA receptor function by direct protein-protein interactions with the dopamine D1 receptor. Cell 111:219

27. Flores-Hernandez J, Cepeda C, Hernandez-Echeagaray E, Calvert CR, Jokel ES, Fienberg AA, Greengard P, Levine MS 2002 Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. J Neurophysiol 88:3010

28. Fiorentini C, Rizzetti MC, Busi C, Bontempi S, Collo G, Spano P, Missale C. 2006 Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat. Mol Pharmacol 69:805

29. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P 2001 BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411:86

30. Bezard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, Gross C, Sokoloff P 2003 Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 9:762

31. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P. 2002 Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 87:5545

32. Lundblad M, Andersson M, Winkler C, Kirk D, Wierup N and Cenci MA 2002 Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. Eur J Neurosci 15:120

33. Genedani S, Rasio G, Cortelli P, Antonelli F, Guidolin D, Galantucci M, Fuxe K, Agnati LF. 2004 Studies on homocysteine and dehydroepiandrosterone sulphate plasma levels in Alzheimer's disease patients and in Parkinson's disease patients. Neurotox Res 6:327

34. Agnati LF, Fuxe K, Torvinen M, Genedani S, Franco R, Watson S, Nussdorfer GG, Leo G, Guidolin D 2005 New methods to evaluate colocalization of fluorophores in immunocytochemical preparations as exemplified by a study on A2A and D2 receptors in Chinese hamster ovary cells. J Histochem Cytochem 53:941

35. Missale C, Nisoli E, Liberini P, Rizzonelli P, Memo M, Buonamici M, Rossi A, Spano PF. 1989 Repeated reserpine administration up-regulates the transduction mechanisms of D1 receptors without changing the density of [3H]-SCH 23390 binding. Brain Res 483:117
36. Missale C, Boroni F, Castelletti L, Dal Toso R, Gabellini N, Sigala S, Spano PF 1991 Lack of coupling of D2 receptors to adenylate cyclase in GH3 cells exposed to epidermal growth factor. J Biol Chem 266:23392
37. Memo M, Castelletti L, Missale C, Valerio A, Carruba MO, Spano PF 1986 Dopaminergic inhibition of prolactin release and calcium influx induced by neurotensin in anterior pituitary is independent of cyclic AMP. J Neurochem 47:1689
38. Schallert T, Fleming SM, Leasure JL, Tillerson JL and Bland ST 2000 CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacol 39:777
39. Torvinen M, Marcellino D, Canals M, Agnati L, Lluis C, Franco R, Fuxe K 2005 Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes. Mol Pharmacol 67:400

Keywords

RECEPTOR MOSAICS, DOPAMINE RECEPTORS, ADENOSINE RECEPTORS, GLUTAMATE RECEPTORS, DESENSITIZATION, RECEPTOR TRAFFICKING, BASAL GANGLIA, ANIMAL MODELS OF PARKINSON'S DISEASE, HETERODIMERIZATION